Takeda Pharmaceutical (TAK) holder to sell 54,210 ADSs after RSU vesting

Rhea-AI Filing Summary

A holder of Takeda Pharmaceutical Company Limited American Depositary Shares plans to sell up to 54,210 ADSs on the NYSE, through Interactive Brokers LLC, with an indicated aggregate market value of $908,019.02 as of 07/13/2026.

The securities relate to Restricted Stock Unit awards that vested on 07/01/2026, when 114,144 ADSs were acquired as compensation.

Filing Explained

The filing reports a proposed 114,144-ADS disposition from vested compensation, without establishing completion or new dilution for existing holders.

The July 13 Form 144 lists 114,144 ADSs under securities to be sold, but the filing does not establish that the ADSs were sold.

The ADSs are identified as acquired through vested restricted stock unit awards and classified as compensation. This is a disposition by the filer, not a Takeda issuance, so the filing discloses no new ADS issuance or dilution for existing common holders.

The provided filing contains no trading-plan disclosure, sale price, or remaining-holdings information, so the size of any change in the filer's ownership cannot be assessed.

Key Figures

ADSs planned for sale: 54,210 ADSs Aggregate market value: $908,019.02 ADSs acquired via RSU vesting: 114,144 ADSs +2 more

5 metrics

ADSs planned for sale 54,210 ADSs Amount of Takeda ADSs indicated for sale on NYSE

Aggregate market value $908,019.02 Indicated value of ADSs planned for sale as of 07/13/2026

ADSs acquired via RSU vesting 114,144 ADSs Takeda ADSs received from Restricted Stock Unit Awards on 07/01/2026

RSU vesting date 07/01/2026 Date RSU awards vested and ADSs were received as compensation

Planned sale date 07/13/2026 Trade date associated with planned NYSE sale of ADSs

Key Terms

American Depositary Shares (ADSs), Restricted Stock Unit Awards, compensation

3 terms

American Depositary Shares (ADSs) financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards financial

"ADSs | 07/01/2026 | Restricted Stock Unit Awards - Vested."

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

compensation financial

"114144 | 07/01/2026 | Compensation"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 06:30 AM Accepted by SEC EDGAR 07/13/2026 - 06:21 AM Learn about SEC filing dates

FAQ

What amount of Takeda (TAK) ADSs is planned for sale under this notice?

The filing indicates a planned sale of up to 54,210 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited on the NYSE, routed through Interactive Brokers LLC.

What is the aggregate market value of the Takeda (TAK) ADSs covered by this sale?

The planned sale covers Takeda ADSs with an indicated aggregate market value of approximately $908,019.02, based on the information tied to the 07/13/2026 trade date on the NYSE.

When were the Takeda (TAK) ADSs underlying this Form 144 acquired?

The ADSs were acquired on 07/01/2026 in connection with Restricted Stock Unit (RSU) awards that vested on that date and were characterized as compensation.

How many Takeda (TAK) ADSs were received from vested RSU awards?

The holder received 114,144 ADSs of Takeda Pharmaceutical Company Limited on 07/01/2026 as a result of Restricted Stock Unit Awards - Vested granted as compensation.

On which exchange will the Takeda (TAK) ADSs be sold?

The planned transaction involves selling Takeda American Depositary Shares on the NYSE, with Interactive Brokers LLC listed as the broker handling the sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	54210	908019.02	143310556	07/13/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2026	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			114144	07/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)